TABLE 3.
Sources of 54 nonreplicate cultures by predominant AFLP type with antimicrobial susceptibilities
| AFLP type (n) | Culture sourcea |
No. susceptible to drugb/no. of total isolates |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wound | Respiratory | Skin surveillance | Bloodstream | Urine | Unknown | CTZ | OFX | TET | AM-S | IMP | TMS | MER | AMK | TOB | PIP | GEN | NET | |
| Inpatient | ||||||||||||||||||
| 16 (15) | 6 | 5 | 2 | 1 | 0 | 1 | 10/15 | 0/15 | 2/15 | 15/15 | 7/15 | 0/15 | 4/15 | 15/15 | 4/15 | 0/15 | 4/15 | 15/15 |
| 18 (11) | 5 | 0 | 4 | 0 | 1 | 1 | 8/11 | 0/11 | 0/11 | 11/11 | 0/11 | 0/11 | 0/11 | 11/11 | 0/11 | 0/11 | 0/11 | 11/11 |
| 11 (6) | 0 | 2 | 3 | 1 | 0 | 0 | 0/6 | 0/6 | 0/6 | 0/6 | 6/6 | 0/6 | 6/6 | 5/6 | 6/6 | 0/6 | 0/6 | 6/6 |
| 9 (4) | 1 | 1 | 2 | 0 | 0 | 0 | 0/4 | 0/4 | 0/4 | 0/4 | 4/4 | 0/4 | 4/4 | 1/4 | 1/4 | 0/4 | 0/4 | 1/4 |
| All others (15) | 8 | 2 | 2 | 1 | 2 | 0 | 6/15 | 5/15 | 4/15 | 10/15 | 14/15 | 6/15 | 14/15 | 10/15 | 7/15 | 3/15 | 4/15 | 13/15 |
| Outpatient | ||||||||||||||||||
| All others (3) | 0 | 0 | 3 | 0 | 0 | 0 | 3/3 | 3/3 | 2/3 | 3/3 | 3/3 | 1/3 | 3/3 | 3/3 | 3/3 | 2/3 | 3/3 | 3/3 |
| Total | 20 | 10 | 16 | 3 | 3 | 2 | ||||||||||||
a
No significant association between any source and AFLP type (Fisher's exact test, P values not shown).
b
CTZ, ceftazidime; OFX, ofloxacin; TET, tetracycline; AM-S, ampicillin-sulbactam; IMP, imipenem; TMS, trimethroprim-sulfamethoxazole; MER, meropenem; AMK, amikacin; TOB, tobramycin; PIP, piperacillin; GEN, gentamicin; NET, netilmicin.